Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Thalomid Promotions For Off-Label Cancer Use Draw FDA Warning

Executive Summary

Thalomid sales representatives have disseminated third-party press releases that promote off-label use of the thalidomide capsules for multiple myeloma, an FDA warning letter to Celgene states.

You may also be interested in...



Rx Promotion Remains Potential Political Liability, Attorneys Warn

Pharmaceutical companies should prepare for increased Congressional scrutiny of promotional activities heading into the 2002 mid-term elections, attorney John Kamp (Wiley, Rein and Faulding, Washington, D.C.) told a Drug Information Association marketing workshop.

Rx Promotion Remains Potential Political Liability, Attorneys Warn

Pharmaceutical companies should prepare for increased Congressional scrutiny of promotional activities heading into the 2002 mid-term elections, attorney John Kamp (Wiley, Rein and Faulding, Washington, D.C.) told a Drug Information Association marketing workshop.

Celgene Seeks Additional Oncologic To Leverage Thalomid Sales Force

Celgene is planning to in-license an oncology product to be detailed alongside Thalomid (thalidomide), CEO John Jackson told the Biotechnology Industry Organization's CEO & Investor Conference in New York City Feb. 21.

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel